| Previous Close | 58.80 |
| Open | 58.18 |
| Bid | 53.29 x 900 |
| Ask | 53.48 x 800 |
| Day's Range | 52.37 - 58.91 |
| 52 Week Range | 7.61 - 65.43 |
| Volume | 348,595 |
| Avg. Volume | 580,257 |
| Market Cap | 3.698B |
| Beta (5Y Monthly) | 1.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.50 |
| Earnings Date | Nov. 02, 2020 - Nov. 06, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 76.75 |
- Zacks
Analysts Estimate ChemoCentryx (CCXI) to Report a Decline in Earnings: What to Look Out for
ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Despite Lacking Profits ChemoCentryx (NASDAQ:CCXI) Seems To Be On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- Zacks
ChemoCentryx's NDA for Autoimmune Disease Drug Accepted by FDA
The FDA accepts ChemoCentryx's (CCXI) NDA for avacopan, for the treatment of ANCA-associated vasculitis.
© 2020 Verizon Media. All rights reserved.
